Search
Formic acid
go.drugbank.com/drugs/DB01942ApprovedInvestigationalIt is an important intermediate in chemical synthesis and occurs naturally, most famously in the venom of bee and ant stings.
Drug Poisoning
go.drugbank.com/conditions/DBCOND0063975Drugs: Sodium phosphate, monobasicSynonyms: Toxicity to various agentsAdavosertib
go.drugbank.com/drugs/DB11740InvestigationalMK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.
MK-0533
go.drugbank.com/drugs/DB15242InvestigationalMK-0533 is under investigation in clinical trial NCT00543959 (Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)).
Sinapic acid
go.drugbank.com/drugs/DB08587ExperimentalSinapic acid is a matrix for matrix-assisted laser desorption technique for protein MW determination. It is also a constituent of propolis.
Cemiplimab
go.drugbank.com/drugs/DB14707ApprovedInvestigationalBy blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses. … [A39201,A254177,L4615] It was later approved to be used in basal cell carcinoma and non-small non-small cell lung cancer.
Sovateltide
go.drugbank.com/drugs/DB06138InvestigationalSPI-1620 is an endothelin B receptor agonist. In animal models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of anticancer agents to the tumor. … It is being developed as an adjunct to chemotherapy.
Pumactant
go.drugbank.com/drugs/DB04955ExperimentalIt is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG).
Poloxamer 188
go.drugbank.com/drugs/DB11333ApprovedP188 was originally approved by the FDA in the 1960s as a therapeutic agent to reduce viscosity in the blood before transfusions, however it is no longer available in any approved products [A27217]. … Composed of two hydrophilic side-chains attached to a hydrophobic center core [A27218], its average molecular weight is 8400 Daltons.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsProducts: Shur-clens Soln 20%Cerliponase alfa
go.drugbank.com/drugs/DB13173ApprovedInvestigational[L51339] It was also approved by the EMA on May 30, 2017 [L51324] and by Health Canada on December 19, 2018. … [L51329] CLN2 is a predominantly pediatric-onset neurodegenerative disease caused by a deficiency in the lysosomal enzyme TPP1, leading to progressive impairment in motor and cognitive function.